PHANTOM: Anastrozole in Patients with Pulmonary Arterial Hypertension
Primary Objective
To determine whether anastrozole (AN) may improve six minute walk distance (6MWD) at 6 months compared to placebo and to assess safety and side effects up to 12 months in pulmonary arterial hypertension (PAH)
Details
Age
Adult
Eligibility
Men and women over 18 years of age
Must have been diagnosed with pulmonary hypertension by a right heart catheterization
Must have PAH which is idiopathic, heritable, drug or toxin induced, associated with connective tissue disease, congenital heart disease, portal hypertension or HIV and receiving treatment for PAH
Cannot be pregnant, of child bearing potential or on any hormone replacement therapy
Must be able to preform a 6 min walk test
Must not have a history of Breast Cancer
Must not have untreated obstructive sleep apnea
Locations
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Todd Bull
Study ID
Protocol Number: 17-0536
More information available at ClinicalTrials.gov: NCT03229499
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers